✦ LIBER ✦

P92 Low morbidity and no mortality of high-dose cyclophosphamide, thiotepa and mitoxantrone plus autologous peripheral blood stem cell support for high-risk breast cancer patients

✍ Scribed by N. Kröger; W.H. Krüger; F. Gieseking; F. Jaenicke; W. Schultze; H. Fuss; V. Möbus; M. Königsmann; W.E. Berdel; K. Schäfer-Eckert; H. Wandt; B. Metzner; H.J. Illiger; N. Frickhofen; G. Wulf; B. Wörmann; K. Kolbe; D.K. Hossfeld; H. Maas; W. Jonat; A.R. Zander

Book ID: 117665527
Publisher: Elsevier Science
Year: 1998
Tongue: English
Weight: 164 KB
Volume: 34
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(97)89309-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase I trial of high-dose paclitaxel,

A phase I trial of high-dose paclitaxel, cyclophosphamide and mitoxantrone with autologous blood stem cell support for the treatment of metastatic breast cancer

✍ S Glück; C Germond; P Lopez; P Cano; M Dorreen; T Koski; A Arnold; H Dulude; G G 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 79 KB

The use of high-dose cyclophosphamide, c

The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy

✍ Yee Chung Cheng; Gabriela Rondón; Ying Yang; Terry L. Smith; James L. Gajewski; 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 274 KB

High dose chemotherapy (HDCT) with mitox

High dose chemotherapy (HDCT) with mitoxantrone, cyclophosphamide, vinblastine or carboplatin with bone marrow support in metastatic breast cancer (MBC): Role of autologous peripheral blood stem cell transplantation (PBSCT) and cytokines

✍ Nabholtz, J.M.; Gluck, S. 📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 181 KB

P53 is the strongest predictor of surviv

P53 is the strongest predictor of survival in high-risk primary breast cancer patients undergoing high-dose chemotherapy with autologous blood stem cell support

✍ Manfred Hensel; Andreas Schneeweiss; Hans-Peter Sinn; Gerlinde Egerer; Erich Sol 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 French ⚖ 129 KB 👁 3 views

## Abstract Our purpose was to determine the predictive value of tumor biologic parameters in patients with HRPBC who received HDCT with ASCT as first‐line treatment. From September 1992 to May 2000, 149 stage II or III HRPBC patients were enrolled in a single‐arm trial using a tandem HDCT regimen

The antiemetic efficacy of granisetron p

The antiemetic efficacy of granisetron plus dexamethasone, haloperidol and loracepam in breast cancer patients treated with high-dose chemotherapy with peripheral blood stem-cell support

✍ M. A. Climent; Javier Palau; Amparo Ruiz; Virtudes Soriano; Eduardo Aznar; Teres 📂 Article 📅 1998 🏛 Springer-Verlag 🌐 English ⚖ 23 KB

Repetitive high-dose therapy with cyclop

Repetitive high-dose therapy with cyclophosphamide, thiotepa and docetaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study

✍ Prince, H M; Rischin, D; Toner, G C; Seymour, J F; Blakey, D; Gates, P; Eerhard, 📂 Article 📅 2000 🏛 Nature Publishing Group 🌐 English ⚖ 78 KB